dysadherin
DESCRIPTION
Supplemental Fig. 1. Dysadherin. CK19. 265. 200. 100. 195. 1. Relative mRNA Expression. Relative mRNA Expression. 125. 10. 5. 0. 0. Hep3B. Hep3B. Hep3B. Hep3B. HepG2. HepG2. HepG2. HepG2. SK-Hep1. SK-Hep1. SK-Hep1. SK-Hep1. PLC/PRF/5. PLC/PRF/5. PLC/PRF/5. PLC/PRF/5. - PowerPoint PPT PresentationTRANSCRIPT
Dysadherin
CD90CD117
0
5
10
195
265
0
4
8
140
160
0
1
2
6
12
Rel
ativ
e m
RN
A E
xpre
ssio
n
PLC/PRF/5
Hep3B
Huh7
HepG2
SK-Hep1
125
Rel
ativ
e m
RN
A E
xpre
ssio
n
Rel
ativ
e m
RN
A E
xpre
ssio
n0
1
100200
Rel
ativ
e m
RN
A E
xpre
ssio
n
CK19
PLC/PRF/5
Hep3B
Huh7
HepG2
SK-Hep1
PLC/PRF/5
Hep3B
Huh7
HepG2
SK-Hep1
PLC/PRF/5
Hep3B
Huh7
HepG2
SK-Hep1
Supplemental Fig. 1
0.0
0.5
1.0
1.5
CTLsiCTL
siDys
*NS *NS *NS
Re
lati
ve
mR
NA
Ex
pre
ss
ion
A
B
0
200
400
600
0
200
400
600
0
300
600
900
CTLsiCTL
siDys
Th
e N
um
ber
of
Tu
mo
rsp
her
e
*NS *NS*NS
Huh7 HepG2Hep3B
Huh7 HepG2Hep3B
***
***
Supplemental Fig. 2
CTLsiC
TL
siABCB1
CTLsiC
TL
siABCB1
AV1 AL3-1
ABCB1
β-actin
A
B
0
2
4
6
8
CTLsiC
TL
siABCB1
CTLsiC
TL
siABCB1
AV1
AL3-1
*
*NS
NS
*
*
Supplemental Fig. 3
.
CisplatinDoxorubicin
.
Methotrexate
Mitoxantrone
Paclitaxel
.
.
Topotecan
.
.Gyorffy study
Vinblastine
.
.
Resistantcell lines
SensitiveCell lines
n=6 n=20
Resistantcell lines
SensitiveCell lines
n=20 n=6
Resistantcell lines
SensitiveCell lines
n=19 n=5
Resistantcell lines
SensitiveCell lines
n=3 n=27
Resistantcell lines
SensitiveCell lines
n=15 n=9
Resistantcell lines
SensitiveCell lines
n=6 n=15
Resistantcell lines
SensitiveCell lines
n=3 n=22
0.2
-0.0
-0.2
-0.4
-0.6
4
3
2
1
0
4
3
2
1
0
0.5
0.0
-0.5
0.5
0.0
-0.5
0.5
0.0
-0.5
0.5
0.0
-0.5
Supplemental Fig. 4
Supplemental Fig. 5